Arthneeti
Latest: Corona Remedies Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
CR

Corona Remedies

Q1 FY27Pharmaceuticals & Biotechnology

Corona Remedies Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹2,100
Market cap₹13.1K Cr
P/E61.9
Updated25 Aug 2026
Read3 min read

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

The short version

CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall. - The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually. - Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. CORONA Remedies targets a 15% organic revenue growth and 20% PAT growth for FY27 and near-term future.

From Corona Remedies's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall.
  • The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually.
  • Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. 5x IPM).
  • Price-led growth and new product introductions also contribute, with prices growing at 8.7% versus IPM’s 5.6%, and new product introductions at 3.4% versus IPM’s 2.9%.
  • Strong ramp-up expected in IVF business over next 2-3 quarters as the MR taskforce scales efforts.

2 more points from Corona Remedies's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Corona Remedies said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Corona Remedies Limited has recently commissioned a new EU GMP approved hormonal manufacturing plant with a capex of INR 130 crores.
  • The hormonal plant started operations on June 30, 2026, and is expected to have an asset turnover of less than 1x in FY27, gradually increasing to 2-3x over the next three years.
  • The company is in the final stages of preparing dossiers for this plant to enable international market entry, targeting FY28-29 for international scale-up.
  • Additional capital investments related to brand acquisitions include the Wokadine brand (acquired for INR 97 crores plus GST), amortized over 10 years, and a Bayer brand acquired for INR 7 crores.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Corona Remedies said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Corona Remedies said on order book & pipeline — free account, 30 seconds.

Corona Remedies — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹441 Cr, net profit ₹60 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Corona Remedies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Corona Remedies and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Corona Remedies Q1 FY27 results?

CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall. - The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually. - Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. CORONA Remedies targets a 15% organic revenue growth and 20% PAT growth for FY27 and near-term future.

What is Corona Remedies share price analysis?

Corona Remedies currently shows a below-average growth signal. The stock trades at a P/E of 61.9 with a market cap of ₹13,104 Cr. Investors should review the full earnings analysis for detailed insights.

Is Corona Remedies planning capital expenditure?

Corona Remedies Limited has recently commissioned a new EU GMP approved hormonal manufacturing plant with a capex of INR 130 crores.

Keep Corona Remedies on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.